The estimated Net Worth of Ronald A Matricaria is at least $3.18 Milion dollars as of 16 March 2020. Mr. Matricaria owns over 20,000 units of Orthofix Medical Inc stock worth over $2,695,939 and over the last 21 years he sold OFIX stock worth over $0. In addition, he makes $485,023 as Independent Chairman of the Board at Orthofix Medical Inc.
Ronald has made over 5 trades of the Orthofix Medical Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of OFIX stock worth $485,000 on 16 March 2020.
The largest trade he's ever made was buying 50,000 units of Orthofix Medical Inc stock on 1 June 2015 worth over $1,632,500. On average, Ronald trades about 4,583 units every 131 days since 2004. As of 16 March 2020 he still owns at least 154,939 units of Orthofix Medical Inc stock.
You can see the complete history of Mr. Matricaria stock trades at the bottom of the page.
Ronald A. Matricaria serves as Independent Chairman of the Board of the Company. He was appointed to the Board in March 2014. He has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company, Inc. From April 1993 to May 1999, he served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors from January 1995 to May 2002. Prior to joining St. Jude Medical, Mr. Matricaria spent 23 years with Eli Lilly and Company, Inc., where his last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. He also served as President of Eli Lilly International Corporation, as well as President of its Medical Device Division. Until recently, he served as a director of Kinaxis Inc. a SaaS based software company traded on the Toronto Stock Exchange, and as Chairman of the Board at Volcano Corporation and as a member of the Boards of Phoenix Children’s Hospital and Life Technologies Corporation. Additionally, Mr. Matricaria previously has served on the board of a number of other public and private companies including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association (AdvaMed), the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota.
As the Independent Chairman of the Board of Orthofix Medical Inc, the total compensation of Ronald Matricaria at Orthofix Medical Inc is $485,023. There are 7 executives at Orthofix Medical Inc getting paid more, with Jon Serbousek having the highest compensation of $4,076,200.
Ronald Matricaria is 77, he's been the Independent Chairman of the Board of Orthofix Medical Inc since 2019. There are no older and 17 younger executives at Orthofix Medical Inc.
Ronald's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Over the last 22 years, insiders at Orthofix Medical Inc have traded over $19,062,472 worth of Orthofix Medical Inc stock and bought 182,076 units worth $5,806,101 . The most active insiders traders include Stuart Essig, Charles R. Kummeth oraz Alexis V Lukianov. On average, Orthofix Medical Inc executives and independent directors trade stock every 53 days with the average trade being worth of $179,237. The most recent stock trade was executed by Kevin J. Kenny on 8 January 2024, trading 5,959 units of OFIX stock currently worth $103,687.
orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing
Orthofix Medical Inc executives and other stock owners filed with the SEC include: